Table 1.
Study characteristics
| Reference | Region | Perspective | Population | Modeling | Timescale | Discount |
|---|---|---|---|---|---|---|
| Moeremans et al5 | Belgium, Italy, Sweden, UK | Reimbursement authorities | HIV-infected adults | Markov model | Lifetime | Based on local guidelines |
| Long et al6 | St Petersburg, Russia | NA | IDUs and non-IDUs | Dynamic HIV-epidemic model | 20 years | 3% |
| Vijayaraghavan et al7 | South Africa | NA | HIV-positive adults | Markov model | Lifetime | NA |
| Hubben et al8 | The Netherlands | Dutch health care | HIV-infected patients | Markov model | Lifetime | 4%, 1.5% |
| Johnston et al9 | British Columbia, Canada | Payers | Asymptomatic HIV patients | Mathematical model | 30 years | NA |
| Binagwaho et al10 | Rwanda | Health care payers | Pregnant women | NA | Lifetime | 3% |
| Orlando et al11 | Malawi | Private, public | Pregnant women | NA | NA | 15% |
| Brogan et al12 | USA | Societal | HIV-infected adults | Markov model | Lifetime | 3% |
| Simpson et al13 | USA | Payers | Treatment-experienced HIV Patients | Markov model | Lifetime | 3% |
| Badri et al14 | South Africa | Public healthcare system | HIV-infected adults without AIDS and with AIDS | NA | NA | NA |
| Marseille et al15 | Rural Uganda | Societal | HIV-infected patients | NA | 15 years | 3% |
| Rizzardini et al16 | Italy | Lombardy Regional Health Service | Adult HIV subjects who received HAART therapy for the first time | Markov model | 2 years | None |
| Colombo et al17 | Italy | Italian National Health Service | HIV-infected patients | Markov model | 10 years | 3.50% |
| McCabe et al18 | NA | Societal | HIV-infected pregnant women | Mathematical model | Lifetime | 3% |
| Munakata et al19 | NA | Societal | HIV patients on an initial regimen of HAART | Markov model | Lifetime | 3% |
| Colombo et al20 | Italy | Italian health care system | HIV-infected patients | Markov model | 10 years | 3.50% |
| Granich et al21 | South Africa | NA | HIV-infected patients | Epidemic model | 40 years | 3% |
| Fang et al22 | Taiwan | National health insurance | HIV-positive patients and AIDS | NA | NA | NA |
| Ono et al23 | Thailand | NA | HIV-infected patients | Markov model | NA | 3% |
| Badri et al24 | Sub-Saharan Africa | Public health | HIV-infected patients | Markov model | Lifetime | 8% |
| Mauskopf et al25 | NA | NA | HIV-infected patients | Markov model | 25 years | 3% |
| Mauskopf et al26 | USA | NA | Treatment-experienced patients | Markov model | 5 years, lifetime | 3% |
Abbreviations: NA, not applicable; IDUs, injecting drug users; HAART, highly active antiretroviral therapy.